A5028214040- CAR-T cell therapy research
- Integrated Circuits and Semiconductor Failure Analysis
- Lymphoma Diagnosis and Treatment
- Silicon Carbide Semiconductor Technologies
- Virus-based gene therapy research
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Silkworms and Sericulture Research
- Advancements in Semiconductor Devices and Circuit Design
- Viral Infectious Diseases and Gene Expression in Insects
Tel Aviv University
2022-2025
Sheba Medical Center
2023-2025
Pulmonary function tests (PFT) are recommended for hematopoietic cell transplantation (HCT) evaluation. However, their prognostic value in chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We assessed the predictive significance of PFTs and pulmonary comorbidity classifications, per Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI), B-cell lymphoma patients undergoing autologous CD19-CAR-T therapy. Single-center retrospective analysis encompassing 192 with...
Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation end-organ function. Developed using cohort of 149 NHL, revealed inflammatory signature associated high risk CAR-T treatment failure, including increased hazard...
Chimeric antigen receptor T-cells (CAR-T) are widely used for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL). The data CAR-T therapy in patients with extra-nodal (EN) is restricted. We included 126 consecutive DLBCL treated commercially available cells (tisagenlecleucel, n = 100, 79.4% and axicabtagene ciloleucel, 26, 20.6%). At lymphodepletion, 72 (57%) had EN disease, 42 (33%) nodal disease (ND)-only 12 (10%) showed no assessed by PET-CT. There were significant...
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and efficacy CAR patients RT (N=30) compared (N=283) transformed indolent non-Hodgkin (iNHL) (N=141) between April 2016 January 2023. Two-thirds received prior for CLL before 89% them 2 inhibitors. Toxicities were similar other...
AbstractPatients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines. We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in R/R-FL patients treated ≥ 2 All 26 enrolled received CAR T-cell infusion at median 11 days after leukapheresis. Seventy-seven percent had POD24. At enrollment, disease stage was III-IV 85% the patients, 77% high-risk FLIPI score, and progressive...
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Primary mediastinal B- cell lymphoma (PMBCL), a pathobiologically unique subtype of aggressive B lymphoma, has excellent prognosis in front-line setting but dismal outcome as relapse/refractory (r/r) disease. Chimeric antigen receptor (CAR) T therapy shown great efficacy salvage though very few PMBCL patients were included the pivotal trials. Data longer follow-up is needed, well understanding role other...
Abstract Chimeric antigen receptor T-cells (CAR-T) are widely used for the treatment of relapsed/refractory Diffuse large B cell lymphoma (DLBCL). The data CAR-T therapy in patients with extra-nodal(EN) is restricted. We included 126 consecutive DLBCL treated commercially available cells (tisagenlecleucel, n=100, 79.4% and axicabtagene ciloleucel, n=26, 20.6%). At lymphodepletion , 72/126(57%) had EN disease, 42/126(33%) nodal disease (ND)-only 12/126(10%) showed no assessed by PET-CT. There...